Psyence Biomedical Ltd. (PBM)

NASDAQ: PBM · IEX Real-Time Price · USD
1.140
-0.040 (-3.39%)
At close: Mar 28, 2024, 4:00 PM
1.150
+0.010 (0.88%)
After-hours: Mar 28, 2024, 7:46 PM EDT
-3.39%
Market Cap 42.09M
Revenue (ttm) n/a
Net Income (ttm) 1.52M
Shares Out 13.39M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 157,416
Open 1.200
Previous Close 1.180
Day's Range 1.100 - 1.200
52-Week Range 0.514 - 14.550
Beta -0.06
Analysts n/a
Price Target n/a
Earnings Date May 2, 2024

About PBM

Newcourt Acquisition Corp does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Newcourt Acquisition Corp was incorporated in 2021 and is based in Oakland, California. Newcourt Acquisition Corp operates as a subsidiary of Newcourt SPAC Sponsor LLC. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Country Ontario, Canada
Stock Exchange NASDAQ
Ticker Symbol PBM
Full Company Profile

Financial Performance

Financial Statements

News

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc ("Psyence" or the "Company") (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical bu...

2 days ago - GlobeNewsWire

Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin

The study, published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog

10 days ago - GlobeNewsWire

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department ...

13 days ago - GlobeNewsWire

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in men...

16 days ago - GlobeNewsWire

Psyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health ...

17 days ago - GlobeNewsWire

Psyence Biomedical's Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Lt...

23 days ago - GlobeNewsWire

Newcourt Acquisition Corp Announces Continuation of Business Combination Close Process

NEW YORK, NY, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Newcourt Acquisition Corp (“Newcourt”) (NASDAQ: NCAC) announced today that the conditions to closing the business combination (the “Business Combination...

2 months ago - GlobeNewsWire

Newcourt Acquisition Corp Announces Amendment and Supplement to its Definitive Proxy Statement

New York, NY, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Newcourt Acquisition Corp (the “Company”) (NASDAQ: NCAC) announced today that the Company has determined to modify the terms of the proposed amendment (...

1 year ago - GlobeNewsWire